Lumosa Therapeutics Dirección

Dirección controles de criterios 1/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Rong-Jin Lin

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	no data
Participación del CEO	0.6%
Permanencia media de la dirección	2.3yrs
Promedio de permanencia en la Junta Directiva	2.8yrs

Actualizaciones recientes de la dirección

Recent updates

Lumosa Therapeutics'(GTSM:6535) Share Price Is Down 47% Over The Past Five Years.

Mar 10

We're Hopeful That Lumosa Therapeutics (GTSM:6535) Will Use Its Cash Wisely

Nov 24

CEO

Rong-Jin Lin

no data

Permanencia

Mr. Rong-Jin Lin, Ph.D. (hon) serves as Chief Executive Officer, Chairman of the Board and President at Lumosa Therapeutics Co., Ltd. He serves as an Executive Director of Ausnutria Co., Ltd. He serves as...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Rong-Jin Lin	President	no data	sin datos	0.59% NT$ 168.1m
Li Fang Pan	Chief Financial Officer and Manager of the Administrative Office	no data	sin datos	sin datos
Pei-Jiun Chen	Chief Operating Officer	5.6yrs	sin datos	sin datos
Jia Qi Yang	Financial Officer	2.3yrs	sin datos	sin datos
Todd Ban	Head of Business Development Division	no data	sin datos	sin datos
Christopher Aleong	Chief Business Officer	2.2yrs	sin datos	sin datos

2.3yrs

Permanencia media

Equipo directivo experimentado: El equipo directivo de 6535 se considera experimentado (2.3 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Rong-Jin Lin	President	no data	sin datos	0.59% NT$ 168.1m
Wann- Lai Cheng	Director	no data	sin datos	0.29% NT$ 81.6m
Chih-Hsiung Wu	Independent Director	no data	sin datos	0.013% NT$ 3.6m
Fang Wei Ding	Member of the Supervisory Board	no data	sin datos	sin datos
Xue Ling Wang	Member of the Supervisory Board	no data	sin datos	0.28% NT$ 79.8m
Chih-Yung Chin	Independent Director	4.9yrs	sin datos	sin datos
Chong-Hao Tasi	Director	2.8yrs	sin datos	sin datos
Hsueh-Lin Wang	Director	2.8yrs	sin datos	sin datos
Josephine Shen	Independent Director	no data	sin datos	sin datos
Hsin-Jung Lin	Independent Director	less than a year	sin datos	sin datos

2.8yrs

Permanencia media

Junta con experiencia: La junta directiva de 6535 no se considera experimentada (2.8 años de permanencia promedio), lo que sugiere una nueva junta directiva.

Lumosa Therapeutics Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

Lumosa Therapeutics Co., Ltd., Annual General Meeting, May 02, 2024

Less than half of directors are independent

Less than half of directors are independent

Lumosa Therapeutics Co., Ltd., Annual General Meeting, May 24, 2022

Lumosa Therapeutics Co., Ltd. Announces Resignation of Ya-Ting Hsu as Chief Internal Auditor, Effective March 31, 2021

Recent updates

Full year 2023 earnings released: NT$1.47 loss per share (vs NT$3.05 loss in FY 2022)

Lumosa Therapeutics Co., Ltd., Annual General Meeting, May 02, 2024

Lumosa Therapeutics and CHI Memorial Announce New Study for Acute Stroke

New minor risk - Share price stability

Lumosa Therapeutics Co., Ltd. Receives Approval to Initiate Phase 2, Multiple-Dose Study of Its LT3001

Second quarter 2023 earnings released: NT$0.92 loss per share (vs NT$1.20 loss in 2Q 2022)

Full year 2022 earnings released: NT$3.05 loss per share (vs NT$0.64 profit in FY 2021)

Less than half of directors are independent

Second quarter 2022 earnings released: NT$1.20 loss per share (vs NT$0.74 loss in 2Q 2021)

First quarter 2022 earnings released: NT$1.14 loss per share (vs NT$0.46 profit in 1Q 2021)

Less than half of directors are independent

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Lumosa Therapeutics Co., Ltd., Annual General Meeting, May 24, 2022

Lumosa Therapeutics Announces US FDA Clearance of IND Application for a Phase 2 Multi-Dose Study of LT3001 in Patients with Acute Ischemic Stroke

Lumosa Therapeutics Co., Ltd. Announces Lt3001 Granted Fast TrackDesignation for the Treatment of Acute Ischemic Stroke Toexpedite the Drug Registration Process with the US FDA

Lumosa Announces the Completion of the Phase 1Clinical Trial on the Pharmacokinetics of Multiple Dosesand the Drug-Drug Interaction for LT3001

Lumosa Receives an Notification from AMed Regarding the Receipt of an Import Permit from Thai Food and Drug Administration for Naldebain

Lumosa Therapeutics Co., Ltd. announced that it has received TWD 330 million in funding

Investor sentiment improved over the past week

Second quarter 2021 earnings released: NT$0.74 loss per share (vs NT$0.67 loss in 2Q 2020)

Lumosa Therapeutics Co., Ltd. Announces Positive Results from LT3001 Phase 2a Clinical Trial in Acute Ischemic Stroke

Lumosa Therapeutics Co., Ltd. Announces the Granting of the Formulation Patent for LT1001

Patent of Lumosa’s LT5001 Product Granted by Taiwan Intellectual Property Office

First quarter 2021 earnings released: EPS NT$0.46 (vs NT$0.95 loss in 1Q 2020)

Chief Internal Auditor has left the company

Full year 2020 earnings released: NT$2.67 loss per share (vs NT$2.05 loss in FY 2019)

Lumosa Therapeutics Co., Ltd. announced that it expects to receive TWD 99.992 million in funding from Far Glory Life Insurance Co., Ltd., Asset Management Arm

Lumosa Therapeutics Co., Ltd. Announces Resignation of Ya-Ting Hsu as Chief Internal Auditor, Effective March 31, 2021

Lumosa Therapeutics'(GTSM:6535) Share Price Is Down 47% Over The Past Five Years.

Lumosa Therapeutics Co., Ltd. Announces Approval by Korean Intellectual Property Office and European Patent Office for Lumosa's LT3001, A New Drug for Acute Ischemic Stroke

New 90-day low: NT$33.45

Lumosa Therapeutics Receives Market Approval of LT001 from Singapore's Health Science Agency

Lumosa Therapeutics Co., Ltd. to Commence A Multi-Dose,Drug-Drug-Interaction, Phase I Trial of LT3001 for AIS

Lumosa Announces Completion of Enrollment Inphase 2 Clinical Trial of Its LT3001 for Thetreatment of Acute Ischemic Stroke

Lumosa Therapeutics Co., Ltd. announced that it has received TWD 855.5 million in funding from Center Laboratories, Inc. and other investors

We're Hopeful That Lumosa Therapeutics (GTSM:6535) Will Use Its Cash Wisely

Third quarter 2020 earnings released: NT$0.40 loss per share

New 90-day low: NT$33.90

Lumosa and AMed Sign a Supplementary Licensing Agreement for the Licensing of Extended-Release Analgesic Injection in Southeast Asia

First half earnings released

CEO

Permanencia

Equipo directivo

Permanencia media

Miembros de la Junta

Permanencia media